Drugs to treat diseases associated with excess body fat

Lipidio Pharmaceuticals is pioneering a unique approach to treating obesity by leveraging the skin's capabilities as an active endocrine organ. Traditionally viewed as a protective barrier, the skin is now recognized for its role in synthesizing and secreting various hormones and signaling molecules. The company is developing a drug that exploits these skin signaling mechanisms to provide systemic benefits, particularly in achieving significant reductions in weight and total body fat. This innovative strategy highlights the potential of topical treatments in addressing obesity, moving beyond conventional methods.

The company's lead drug candidate, GDD3898, is currently in clinical-stage Phase 2 trials. Lipidio Pharmaceuticals aims to utilize existing efficacy and safety data from previous studies while conducting new clinical trials to further validate the therapeutic potential of GDD3898 for multiple indications, including obesity and sebaceous hyperplasia. This focus on clinical development underscores Lipidio's commitment to advancing its pipeline and exploring the diverse applications of its unique therapeutic approach.

United States

At Lipidio, patients are at the center of all we do. We are passionate about bringing the very best medicines to market to help patients in need. To do this, we leverage our team’s proven drug development track record to identify, develop and transform molecules into important medicines.

Lipidio Pharmaceuticals

Company Details